Pranlukast

Pranlukast.svg

Pranlukast is a leukotriene receptor antagonist (LTRA) used in the management of asthma and allergic rhinitis. It works by blocking the action of leukotrienes, which are chemicals in the body that contribute to inflammation, bronchoconstriction, and mucus production in the airways.

Mechanism of Action

Pranlukast functions by inhibiting the cysteinyl leukotriene receptor 1 (CysLT1). Leukotrienes are inflammatory mediators derived from arachidonic acid through the 5-lipoxygenase pathway. By blocking these receptors, pranlukast reduces inflammation, bronchoconstriction, and mucus secretion, thereby improving airflow and reducing asthma symptoms.

Indications

Pranlukast is primarily indicated for:

• Asthma: It is used as a maintenance treatment to prevent asthma symptoms and improve lung function.
• Allergic rhinitis: It helps in reducing symptoms such as nasal congestion, sneezing, and runny nose.

Dosage and Administration

Pranlukast is typically administered orally in the form of tablets or granules. The dosage may vary based on the patient's age, severity of symptoms, and response to treatment. It is usually taken once or twice daily.

Side Effects

Common side effects of pranlukast include:

• Headache
• Nausea
• Diarrhea
• Abdominal pain

Serious side effects are rare but may include:

• Liver dysfunction
• Hypersensitivity reactions

Contraindications

Pranlukast is contraindicated in patients with:

• Known hypersensitivity to pranlukast or any of its components
• Severe liver impairment

Drug Interactions

Pranlukast may interact with other medications, including:

• Theophylline
• Warfarin
• Aspirin

Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Pharmacokinetics

Pranlukast is well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 2-3 hours after oral administration. It is extensively metabolized in the liver and excreted primarily in the feces.

History

Pranlukast was first approved for use in Japan in 1995. It has since been used in various countries for the management of asthma and allergic rhinitis.

See Also

• Montelukast
• Zafirlukast
• Leukotriene receptor antagonist
• Asthma
• Allergic rhinitis